FindTrial
Sign In

mFOLFIRINOX Treatment Regimen

DRUG5 trials

Sponsors

Medical College of Wisconsin, Hopital Foch, Zhejiang University, Oncolytics Biotech, Shenzhen Xinhe Biomedical

Conditions

Anal Cancer MetastaticBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)Gastric Cancer (GC)Hepatocellular Carcinoma (HCC)Pancreas NeoplasmsPancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Non-resectable

Phase 1

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Not yet recruitingNCT06888648
Zhejiang UniversityPancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
Start: 2025-04-01End: 2028-04-01Target: 30Updated: 2025-03-21
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Active, not recruitingNCT07280377
Oncolytics BiotechAnal Cancer Metastatic, Pancreatic Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified +1
Start: 2021-10-27End: 2028-12-31Target: 122Updated: 2026-05-19
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
RecruitingNCT07594964
Shenzhen Xinhe BiomedicalBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC) +1
Start: 2025-08-25End: 2030-06-30Target: 48Updated: 2026-05-19

Phase 2

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RecruitingNCT04683315
Medical College of WisconsinPancreatic Cancer
Start: 2021-04-01End: 2028-12-31Target: 84Updated: 2026-03-05
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
RecruitingNCT06757244
Hopital FochPancreas Neoplasms
Start: 2025-02-18End: 2028-02-18Target: 35Updated: 2025-03-18

Related Papers

Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods.
2025-12-20
Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes.
2024-08-221 citations